The development and neoplastic progression of human astrocytic tumors appears to result through an accumulation of genetic alterations occurring in a relatively defined order. One such alteration is amplification of the epidermal growth factor receptor (EGFR) gene. This episomal amplification occurs in 40-50% of glioblastomas, which also normally express endogenous receptors. Moreover, a significant fraction of amplified genes are rearranged to speifically eliminate a DNA fragment containing exons 2-7 of the gene, resulting in an in-frame deletion of 801 bp of the coding sequence of the extracellular domain. Here we used retroviral transfer of such a mutant receptor (de 2-7 EGFR) into glioblastoma cells expressing normal endogenous receptors to test whether the mutant receptor was able to augment their growth and malignancy. Western blotting analysis showed that these cells expressed endogenous EGFR of 170 kDa as well as the exogenous de 2-7 EGFR of 140-155 kDa. Although holoEGFRs were phosphorylated on tyrosine residues only after exposure of the cells to liand, de 2-7 EGFRs were constitutively phosphorylated. In tissue culture neither addition ofEGF nor expression of the mutant EGFR affected the rate of cell growth. However, when cells expressing mutant EGFR were implanted into nude mice subcutaneously or intracerebrally, tumorigenic capacity was greatly enhanced. These results suggest that a tumor-specific alteration of the EGFR plays a significant role in tumor progression perhaps by influencing interactions oftumor cells with their microenvironment in ways not easily assayed in vitro.
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The clonal evolution of neoplasms toward increasing malignancy has been ascribed to the accumulation of genetic alterations that are advantageous to growth (1) . This hypothesis has gained experimental support in colorectal cancer (2) , squamous carcinoma of the cervix (3), lymphoid tumors (4) , and gliomas (5) . In the latter case, a series ofevents occurring in a relatively ordered fashion have been identified and include loss of heterozygosity for chromosome 17p (6, 7) , mutation of the p53 gene (5) , deletions of the interferon gene cluster on chromosome 9p (8) , amplification and alteration of the epidermal growth factor receptor (EGFR) gene (9, 10) , and monosomy of chromosome 10 (11, 12) .
The involvement of EGFR in human cancer has been inferred from its ability to confer ligand-dependent transformation to NIH 3T3 cell transfectants (13) and by its frequent gene amplification and overexpression in carcinomas of the breast (14) , ovary (15) , cervix (15) , kidney (15) , and squamous cells (16) . In glial tumors ofthe central nervous system, such alterations are restricted to grade III (anaplastic astrocytoma) and, especially, grade IV (glioblastoma multiforme) disease (10, (17) (18) (19) . Several clinical and histopathological studies have shown that EGFR gene amplification is related to a shorter interval to relapse and poorer survival (17, 20, 21) . Nearly half of tumors examined had significantly amplified EGFR genes (10, 18, 19) and, of these, the majority also show rearrangements ofthe gene resulting in alterations ofits transcript so that such gliomas express both wild-type endogenous EGFR as well as the episomal mutant form. The most common of the rearrangements are genomic alterations leading to deletion of exons 2-7 in the EGFR mRNA, which causes an in-frame truncation of 801 bp in the extracellular domain of the molecule (9, 10, (22) (23) (24) . Introduction of such a cDNA isolated from a glioma into murine NIH 3T3 cells resulted in expression of a constitutively phosphorylated membrane-associated 150-kDa receptor species, which caused weak ligand-independent cell transformation (25) . Despite the common occurrence of these EGFR aberrations in gliomas, virtually all cell lines derived from them lose these features in tissue culture (26) [2] [3] [4] [5] [6] [7] . Cells were selected for G418 resistance and assessed for the presence of EGFR on their cell surfaces by FACS analysis using the Ab-1 monoclonal antibody, which recognizes an epitope shared by wild-type and de 2-7 EGFRs; 85% of the cells were more heavily stained than the parental U87MG cells, indicating expression of the exogenous gene; the 7% of cells that were most brightly stained were sorted and the population (U87MG.AEGFR) was characterized further by FACS analysis. U87MG.AEGFR reacted equally as well as parental cells with the monoclonal antibody Ab-5, which reacted with wild-type but not de 2-7 EGFR, suggesting that this population expressed levels of the endogenous EGFR similar to that of parental cells (Fig. 1A) . However, when cells were stained with Ab-1, the mean of fluorescence intensity for U87MG.AEGFR was 4-5 times higher than that of parental cells (Fig. 1B) (Fig. 2A, lanes 1 and 5) . Endogenous EGFR was tyrosine phosphorylated only when ligand was added to the medium (Fig. 2B, lanes 2 and 6) . Anti Fig. 2A) , the observation that similar amounts ofligand were bound argues that EGF does not bind to the 4-to 5-fold excess amount of de 2-7 EGFR present on the surface of U87MG.AEGFR cells. Effect of Mutant EGFR on Cell Growth in Vitro. Because de 2-7 EGFR was expressed at a high level in glioblastoma cells and was constitutively active as assessed by tyrosine phosphorylation, we analyzed its influence on cellular growth rate. Fig. 3A shows that the growth of these two cell populations was identical when they were cultured in medium containing 10%1 FBS. Since 2% dialyzed serum was the minimum requirement to sustain growth, we cultured U87MG and U87MG.AEGFR cells in medium containing 2% dialyzed FBS and various concentrations of the ligands, EGF, or transforming growth factor a through a concentration range of 0.1-100 ng/ml. In no case did either ligand affect the growth rates of either cell population and, although U87MG.AEGFR grew slightly faster than U87MG in medium containing 2% dialyzed serum, their saturation densities were the same (Fig. 3B) (Fig. 4) . U87MG.AEGFR caused palpable tumors in 1 wk when 1 x 106 cells were inoculated, whereas the same number of parental U87MG cells required 3 wk to grow to a similar extent; at 1 x 106 cell inoculation, U87MG.AEGFR and U87MG cells required 2 and 5 wk, respectively, to form tumor masses of 1 cm3. Even when the number of U87MG.AEGFR cells implanted was reduced 5-fold to 2 x 10', they still grew more vigorously than U87MG cells, as shown in Fig. 4 .
To determine whether this growth advantage had site specificity, the glioblastoma cells were stereotactically implanted into the brains of nude mice. Cells (2 x 10') were inoculated and after 2 wk, three ofthree animals that received U87MG.AEGFR cells had tumors of 5 mm diameter or greater, whereas only one of five mice implanted with U87MG cells developed a tumor that had a diameter of2 mm. Examples are shown in Fig. 5 . Four animals that received 5 x 10' U87MG.AEGFR cells died within 4 wk after implan- Previous studies showed that amplification of EGFR expression is an unstable situation in vitro (26) . To Fig. 2 ), indicating stability of expression of the mutant E1GFR (data not shown).
Moreover, the expression of EGFRs In U87MG.AEGFR and U87MG tumor cells was homogeneous as shown by the immunohistochemical staining of cryostat sections (Fig. 5) .
DISCUSSION
Expression of a mutant EGFR, which occurs commonly in human glial tumors, enhances the tumorigenic activity of U87MG glioblastoma cells in vivo in the absence of detectable in vitro growth advantages. Holo-EGFR is activated by ligand binding, which causes rapid dimerization (45) , conformational change (46), activation of its intrinsic protein-tyrosine kinase activity, and autophosphorylation (47) . Binding ofligand to the receptor also induces receptor interalizaton, downregulation, and attenuation of signaling (48) . Thus, EGFR activities are normally under stringent positive as well as negative regulation. Disruption ofthe control process by mutations that either affect ligand-dependent tyrosine kinase activation mechanisms or impair ligand-induced receptor internalization may then lead to a constitutive elevation of receptor activity (48, 49) . The mutant receptor we studied here may represent the former case, since it is constitutively tyrosine phosphorylated. Deletion extracellular domain appears to mimic the effect of ligand binding to the receptor, thereby inducing the active conformational change of the receptor and, as a consequence, activating the intrinsic tyrosine kinase activity and so enhancing their tumorigenic activity analogous to v-erbB (40, 41 
